WINNERSH, England, Nov. 2 /PRNewswire/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer, will participate in the Cowen and Company 7th Annual Global Health Care Conference to be held November 7-8, 2006 at the Landmark Hotel in London. Mr. Sturge is scheduled to present an overview of the Company's business activities and product pipeline at 16:50 GMT on Wednesday, November 8, 2006. Investors may access a live webcast of the presentation at http://www.vernalis.com/ under the Investor Relations tab. The presentation will be archived for 3 months. About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders. The company has seven products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis has established a US commercial operation to promote Apokyn(R) and co-promote Frova(R) alongside its North American licensing partner, Endo Pharmaceuticals, progressing the company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company. For further information about Vernalis, please visit http://www.vernalis.com/. Enquiries: Vernalis plc +44 (0) 118 977 3133 Simon Sturge, Chief Executive Officer Tony Weir, Chief Financial Officer Julia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959 Jon Coles Justine McIlroy Lazar Partners Ltd Gregory Gin 212-867-1762 DATASOURCE: Vernalis plc CONTACT: Simon Sturge, Chief Executive Officer; Tony Weir, Chief Financial Officer; or Julia Wilson, Head of Corporate Communications, all of Vernalis plc, +44-(0)-118-977-3133; Jon Coles or Justine McIlroy, both of Brunswick Group, +44-(0)-20-7404-5959; or Gregory Gin, Lazar Partners Ltd, +1-212-867-1762 Web site: http://www.vernalis.com/

Copyright